Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe
A. E. Johnston(Rothamsted Research), José Luis Zamorano(Hospital Universitario Ramón y Cajal), Björn Dahlöf(Thermo Fisher Scientific (Sweden)), David Albert Jones(Oregon Health & Science University), Kate Hill(SmartPractice (United States)), Roland Asmar(Foundation for laboratory medicine), Michael Livingston, Michael Sobanja(Retford Hospital), Enrico Agabiti Rosei(University of Brescia), Jens Jordan(Deutsches Zentrum für Luft- und Raumfahrt e. V. (DLR)), G. A. MacGregor, Panagiotis Stafylas(Aristotle University of Thessaloniki)
Cited by 49
Related Papers
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
|The Lancet|1998|5.8k
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
|European Heart Journal|2016|3.2k
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
|The Lancet|2002|1.6k
Hypertension
|Nature Reviews Disease Primers|2018|1.1k